{"generic":"Polidocanol","drugs":["Polidocanol","Varithena"],"mono":{"0":{"id":"929611-s-0","title":"Generic Names","mono":"Polidocanol"},"1":{"id":"929611-s-1","title":"Dosing and Indications","sub":{"0":{"id":"929611-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Varicose veins of lower extremity:<\/b> (Asclera[TM] injectable, spider veins, 1 mm or less in diameter) inject 0.1 to 0.3 mL of 0.5% solution IV into each vein intended for sclerosis; MAX 10 mL per treatment session<\/li><li><b>Varicose veins of lower extremity:<\/b> (Asclera[TM] injectable, reticular veins, 1 to 3 mm in diameter) inject 0.1 to 0.3 mL of 1% solution IV into each vein intended for sclerosis; MAX 10 mL per treatment session<\/li><li><b>Varicose veins of lower extremity:<\/b> (Varithena[TM] injectable foam) inject up to 5 mL IV using ultrasound guidance; MAX 5 mL per injection, 15 mL per session; separate repeat treatment sessions by at least 5 days<\/li><\/ul>"},"1":{"id":"929611-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients "},"3":{"id":"929611-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Varicose veins of lower extremity<br\/>"}}},"3":{"id":"929611-s-3","title":"Contraindications\/Warnings","sub":[{"id":"929611-s-3-9","title":"Contraindications","mono":"<ul><li>known allergy (anaphylaxis) to polidocanol<\/li><li>thromboembolic disease, acute<\/li><\/ul>"},{"id":"929611-s-3-10","title":"Precautions","mono":"<ul><li>allergic reactions, some severe and fatal, have been reported; increased risk with use of larger volumes (greater than 3 mL of IV solution); monitor patient for at least 10 minutes following injection<\/li><li>tissue ischemia, necrosis, or gangrene may occur with intra-arterial injection or extravasation; patients with underlying arterial disease (eg, peripheral arteriosclerosis, thromboangiitis obliterans) may be at increased risk; consult vascular surgeon immediately if intra-arterial injection occurs (IV foam)<\/li><li>venous thrombosis may occur; increased risk in patients with reduced mobility, recent (within 3 months) major surgery, a history of DVT or pulmonary embolism, prolonged hospitalization, or pregnancy; monitoring recommended (IV foam)<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"929611-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"929611-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"929611-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Dermatologic:<\/b>Injection site bruising (foam, 15.4%; solution, 42%), Injection site irritation (41%), Injection site pain (10.7% to 24%), Injection site pigmentation change (38%), Injection site pruritus (19%)<br\/><b>Serious<\/b><br\/><b>Immunologic:<\/b>Anaphylaxis<br\/>"},"6":{"id":"929611-s-6","title":"Drug Name Info","sub":{"0":{"id":"929611-s-6-17","title":"US Trade Names","mono":"Varithena<br\/>"},"2":{"id":"929611-s-6-19","title":"Class","mono":"Sclerosing Agent<br\/>"},"3":{"id":"929611-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"929611-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"929611-s-7","title":"Mechanism Of Action","mono":"Polidocanol, a non-ionic detergent, is a sclerosing agent that produces endothelial damage in a concentration- and volume-dependent manner. Following injection of polidocanol into the vein, platelets aggregate and attach to the venous wall forming a dense network of platelets, cellular debris, and fibrin which subsequently occlude the vein. The occluded vein is then replaced with connective fibrous tissue. The injectable foam of polidocanol (Varithena[TM]) that is part of the drug\/device combination product displaces blood from the vein prior to the release of the sclerosing agent, polidocanol.<br\/>"},"8":{"id":"929611-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"929611-s-8-23","title":"Absorption","mono":"Tmax (Varithena[TM]): within 15 minutes (after first dose); within 5 minutes (after second dose) <br\/>"},"1":{"id":"929611-s-8-24","title":"Distribution","mono":"Vd: 35 to 82 L (Varithena[TM]) <br\/>"},"3":{"id":"929611-s-8-26","title":"Excretion","mono":"Clearance: 0.2 to 0.4 L\/min (Varithena[TM]) <br\/>"},"4":{"id":"929611-s-8-27","title":"Elimination Half Life","mono":"<ul><li>1.5 hours (Asclera[TM])<\/li><li>102 to 153 minutes (Varithena[TM])<\/li><\/ul>"}}},"9":{"id":"929611-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>(Asclera[TM] injectable) for IV use only<\/li><li>(Asclera[TM] injectable) using a syringe with a fine needle (26- or 30-gauge); insert tangentially into the vein and inject slowly<\/li><li>(Asclera[TM] injectable) apply gentle pressure during injection to prevent vein rupture; following removal of the needle and covering of the injection site, apply compression with a bandage or stocking and maintain compression for 2 to 3 days (spider veins) or 5 to 7 days (reticular veins) to reduce the risk of DVT<\/li><li>(Asclera[TM] injectable) patient should walk for 15 to 20 minutes following treatment; patient should be monitored during this period for potential allergic or anaphylactic reaction<\/li><li>(Varithena[TM] injectable foam, for IV use under ultrasound guidance only<\/li><li>(Varithena[TM] injectable foam) do not shake the canister<\/li><li>(Varithena[TM] injectable foam) use a new transfer unit for each session; use a new sterile syringe after each injection<\/li><li>(Varithena[TM] injectable foam) 16 to 22 gauge and 40- to 50-mm IV catheter or micropuncture sets are recommended for venous access<\/li><li>(Varithena[TM] injectable foam) prefill manometer tube with sterile heparinized NS solution and connect to the IV catheter; confirm venous access via aspiration with a syringe<\/li><li>(Varithena[TM] injectable foam) elevate patient leg to approximately 45 degrees<\/li><li>(Varithena[TM] injectable foam) remove canisters from pouch and place upright, removing safety clip from between canisters<\/li><li>(Varithena[TM] injectable foam) twist canisters together clockwise until they come to a stop and the marks on the collars are aligned to start gas transfer<\/li><li>(Varithena[TM] injectable foam) maintain canisters in upright position for exactly 1 minute while the they are gassing; during this time, open a new Varithena(TM) Transfer Unit blister pack, but leave it in the package<\/li><li>(Varithena[TM] injectable foam) after 1 minute, twist the 2 canisters together by turning them the opposite direction of the previous twisting (counterclockwise)<\/li><li>(Varithena[TM] injectable foam) separate the upper (oxygen, white collar) canister from the lower (polidocanol, blue collar) canister by pulling upright; leave the polidocanol canister in an upright position; record date and time on the label<\/li><li>(Varithena[TM] injectable foam) remove transfer unit and immediately place on top of the blue polidocanol canister by gently rotating the unit clockwise until it drops into the collar threads; twist the unit clockwise until it reaches a stop; the system is now activated and ready for use<\/li><li>(Varithena[TM] injectable foam) foam may be generated for immediate use once the cannula is in situ, the patient's leg is elevated, and the saphenofemoral junction is under ultrasound view<\/li><li>(Varithena[TM] injectable foam) connect new 10-mL low-silicone syringe to transfer unit; prime syringe with downward pressure on unit to produce foam; fill syringe to between 3 and 5 mL; push syringe plunger to fully discard contents back into unit's waste container.<\/li><li>(Varithena[TM] injectable foam) hold syringe plunger in place; apply downward pressure to transfer unit to begin purge cycle; do not pull back on the syringe plunger (ie, do not aspirate the foam); inspect foam within transfer unit to assure visible air bubbles have been expelled (less than 1 second); release plunger allowing syringe to fill to desired volume (up to 5 mL); wait 10 seconds to allow pressure to equalize before removing syringe from transfer unit<\/li><li>(Varithena[TM] injectable foam) before injecting, inspect syringe for visible bubbles, and if present, discard foam and refill from transfer unit<\/li><li>(Varithena[TM] injectable foam) administer injectable foam within 75 seconds of extraction from canister<\/li><li>(Varithena[TM] injectable foam) may administer up to 5 mL per injection and up to 15 mL per session under ultrasound guidance; inject at a rate of approximately 1 mL\/second in the great saphenous vein or 0.5 mL\/second in accessory veins and varicosities<\/li><li>(Varithena[TM] injectable foam) apply compression bandaging and stockings and have the patient walk for at least 10 minutes; maintain compression for 2 weeks posttreatment<\/li><li>(Varithena[TM] injectable foam) separate treatment sessions by at least 5 days<\/li><li>do not remove transfer unit from the canister if the canister is to be stored; the activated canister may be stored at room temperature for 7 days with a transfer unit in place; replace transfer unit just prior to next treatment session<\/li><\/ul>"},"10":{"id":"929611-s-10","title":"Monitoring","mono":"<ul><li>improvement in appearance of uncomplicated spider veins and uncomplicated reticular veins is indicative of efficacy<\/li><li>improvement in the symptoms of superficial venous incompetence is indicative of efficacy<\/li><li>ultrasound; to guide injection of foam and to confirm venospasm of treated vein<\/li><li>walking; for 10  to 20  minutes after treatment<\/li><li>severe allergic reactions (including anaphylactic reaction), for at least 10 minutes after administration<\/li><li>venous thrombosis; after treatment with IV foam<\/li><\/ul>"},"11":{"id":"929611-s-11","title":"How Supplied","mono":"<ul><li><b>Asclera<\/b><br\/>Intravenous Solution: 5 MG\/ML, 10 MG\/ML<br\/><\/li><li><b>Varithena<\/b><br\/>Intravenous Foam: 10 MG\/ML<br\/><\/li><\/ul>"},"13":{"id":"929611-s-13","title":"Clinical Teaching","mono":"<ul><li>Intravenous injection side effects may include injection site hematoma, irritation, discoloration, pain, pruritus, and warmth. Intravenous foam side effects may include pain\/discomfort in extremity, injection site thrombosis (retained coagulum), injection site hematoma or pain, superficial thrombophlebitis, and extravasation.<\/li><li>Warn the patient treated with IV injection to avoid heavy exercise, sunbathing, long airplane flights, and hot baths or saunas for 2 to 3 days after the procedure.<\/li><li>Instruct patients treated with IV injection to wear thigh-high or knee-high compression stockings or support hose continuously for 2 to 3 days after treatment and then for 2 to 3 weeks during the day.<\/li><li>Instruct patients treated with IV foam to keep posttreatment bandages dry and in place for 48 hours and to wear compression stockings on the treated legs continuously for 2 weeks.<\/li><li>Advise the patient treated with IV foam to avoid heavy exercise for 1 week and extended periods of inactivity for 1 month.<\/li><li>Advise patient to walk for at least 15 to 20 minutes (10 minutes for IV foam) after administration and then daily for the following few days (or a month for IV foam).<\/li><\/ul>"}}}